GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (STU:2QK) » Definitions » Net Income (Continuing Operations)

Scholar Rock Holding (STU:2QK) Net Income (Continuing Operations) : €-169.30 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Scholar Rock Holding Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Scholar Rock Holding's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was €-52.31 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was €-169.30 Mil.


Scholar Rock Holding Net Income (Continuing Operations) Historical Data

The historical data trend for Scholar Rock Holding's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scholar Rock Holding Net Income (Continuing Operations) Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial -45.90 -71.09 -116.64 -126.97 -152.03

Scholar Rock Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.78 -35.01 -39.69 -42.30 -52.31

Scholar Rock Holding Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-169.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scholar Rock Holding  (STU:2QK) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Scholar Rock Holding Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Scholar Rock Holding's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Scholar Rock Holding (STU:2QK) Business Description

Industry
Traded in Other Exchanges
Address
301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Scholar Rock Holding (STU:2QK) Headlines

No Headlines